Heat Therapy for Peripheral Arterial Disease (HEATPAD)
NCT: NCT06186505 · WITHDRAWN
Brief Summary
Peripheral arterial disease (PAD) is a disabling condition, with symptoms of muscle cramping or pain on exertion, which can substantially reduce quality of life. This study aims to see if AirGlove device improves participants circulation. This is phase 1 study and will be taken in 3 parts: Phase 1a will be undertaken in 10 healthy volunteers to assess the effects of the AirGlove device on lower limb arterial flow, tissue perfusion, quality of life and product usability following a single session. Phase 1b will be undertaken in 20 participants with intermittent claudication to assess the effects of the AirGlove device on lower limb arterial flow, tissue perfusion, quality of life and product usability both in a single session and following a 12-week trial of heat therapy. Phase 1c will be undertaken in 10 participants with critical limb ischaemia Rutherford stage 4 (rest pain). Lower limb arterial flow, tissue perfusion, pain scores, quality of life, and product usability will be assessed both in a single session and following a 2-12 week trial of heat therapy.
Frequently Asked Questions
What is Heat Therapy for Peripheral Arterial Disease (HEATPAD)?
Heat Therapy for Peripheral Arterial Disease (HEATPAD) is a clinical trial registered under NCT06186505. Current status: WITHDRAWN.
What is the status of NCT06186505?
The current status of NCT06186505 (Heat Therapy for Peripheral Arterial Disease (HEATPAD)) is: WITHDRAWN.
When did Heat Therapy for Peripheral Arterial Disease (HEATPAD) start?
Heat Therapy for Peripheral Arterial Disease (HEATPAD) started on 2025-01-01.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.